Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedJan 31, 2026
DataAggregated Company Financials
Companies318
  • 7D-0.05%
  • 3M19.2%
  • 1Y25.0%
  • YTD1.7%

Over the last 7 days, the Pharma industry has dropped 1.9%, driven by Eli Lilly declining 2.6%. In the past year, the industry has gained 23%. Looking forward, earnings are forecast to grow by 12% annually.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 31 Jan 2026US$2.3tUS$405.1bUS$73.9b20.4x30.8x5.6x
Mon, 29 Dec 2025US$2.3tUS$402.8bUS$71.4b19.9x31.7x5.6x
Wed, 26 Nov 2025US$2.2tUS$402.7bUS$71.4b20.5x30.8x5.5x
Fri, 24 Oct 2025US$1.9tUS$389.2bUS$63.5b18.4x29.6x4.8x
Sun, 21 Sep 2025US$1.8tUS$387.9bUS$60.9b18.4x29x4.6x
Tue, 19 Aug 2025US$1.7tUS$387.8bUS$60.9b19.1x28.6x4.5x
Thu, 17 Jul 2025US$1.7tUS$382.7bUS$61.3b17.9x28.2x4.5x
Sat, 14 Jun 2025US$1.8tUS$382.7bUS$61.2b17.8x29.1x4.7x
Mon, 12 May 2025US$1.7tUS$382.6bUS$61.1b17x27.1x4.3x
Wed, 09 Apr 2025US$1.6tUS$379.9bUS$40.6b15.1x40.5x4.3x
Fri, 07 Mar 2025US$2.0tUS$381.1bUS$39.3b16.3x50x5.2x
Sun, 02 Feb 2025US$1.9tUS$370.4bUS$29.8b18.4x62x5x
Tue, 31 Dec 2024US$1.8tUS$369.3bUS$31.3b16.4x57.7x4.9x
Thu, 28 Nov 2024US$1.9tUS$373.8bUS$30.6b19.8x60.6x5x
Sat, 26 Oct 2024US$2.0tUS$365.3bUS$23.7b17.9x83.8x5.4x
Mon, 23 Sep 2024US$2.0tUS$364.2bUS$25.3b18.9x80.4x5.6x
Wed, 21 Aug 2024US$2.0tUS$362.1bUS$21.8b17.8x92.1x5.5x
Fri, 19 Jul 2024US$2.0tUS$356.5bUS$13.1b16x153.1x5.6x
Sun, 16 Jun 2024US$1.9tUS$358.3bUS$14.1b15.3x137.4x5.4x
Tue, 14 May 2024US$1.9tUS$358.2bUS$13.8b18x134.6x5.2x
Thu, 11 Apr 2024US$1.8tUS$355.1bUS$23.9b23.4x77.3x5.2x
Sat, 09 Mar 2024US$1.9tUS$357.3bUS$20.0b21.9x94x5.3x
Mon, 05 Feb 2024US$1.8tUS$353.1bUS$22.0b31.7x81.4x5.1x
Wed, 03 Jan 2024US$1.7tUS$375.2bUS$33.8b27.4x51x4.6x
Fri, 01 Dec 2023US$1.6tUS$375.1bUS$33.9b26.6x48.2x4.4x
Sun, 29 Oct 2023US$1.6tUS$383.5bUS$46.6b14.2x34.1x4.1x
Tue, 26 Sep 2023US$1.7tUS$381.8bUS$43.9b19.9x38.3x4.4x
Thu, 24 Aug 2023US$1.8tUS$381.6bUS$44.1b19x40.2x4.6x
Sat, 22 Jul 2023US$1.7tUS$394.3bUS$60.5b18.6x28.7x4.4x
Mon, 19 Jun 2023US$1.7tUS$392.8bUS$60.1b19x29x4.4x
Wed, 17 May 2023US$1.7tUS$393.1bUS$60.4b19.3x28.5x4.4x
Fri, 14 Apr 2023US$1.7tUS$401.3bUS$68.5b17.7x24.5x4.2x
Sun, 12 Mar 2023US$1.5tUS$401.1bUS$69.6b17.4x21.9x3.8x
Tue, 07 Feb 2023US$1.7tUS$402.0bUS$69.9b18.2x23.7x4.1x
Price to Earnings Ratio

23.7x


Total Market Cap: US$1.7tTotal Earnings: US$69.9bTotal Revenue: US$402.0bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 53.1x202420252026
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 30.8x which is lower than its 3-year average PE of 53.1x.
  • The 3-year average PS ratio of 4.8x is lower than the industry's current PS ratio of 5.6x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-0.28%
Healthcare-2.46%
Pharma-0.053%
Pharma-0.053%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
JNJ Johnson & JohnsonUS$227.253.2%
+US$17.1b		49.4%PE20.4x
MRK MerckUS$110.271.9%
+US$5.2b		11.6%PE14.4x
PFE PfizerUS$26.443.1%
+US$4.5b		-0.3%PE15.3x
TEVA Teva Pharmaceutical IndustriesUS$34.087.1%
+US$2.6b		92.2%PE27.7x
BMY Bristol-Myers SquibbUS$55.050.7%
+US$814.3m		-6.6%PE18.6x

Latest News

MRK
US$110.27
Merck
7D
1.9%
1Y
11.6%
CORT
US$39.87
Corcept Therapeutics
7D
-9.3%
1Y
-40.4%
OGN
US$8.54
Organon
7D
-12.5%
1Y
-45.1%
JNJ
US$227.25
Johnson & Johnson
7D
3.2%
1Y
49.4%
BMY
US$55.05
Bristol-Myers Squibb
7D
0.7%
1Y
-6.6%
TEVA
US$34.08
Teva Pharmaceutical Industries
7D
7.1%
1Y
92.2%
INDV
US$35.38
Indivior Pharmaceuticals
7D
7.3%
1Y
197.3%
NBY
US$1.86
NovaBay Pharmaceuticals
7D
-60.5%
1Y
179.5%
CRNX
US$49.94
Crinetics Pharmaceuticals
7D
-6.1%
1Y
23.9%
LLY
US$1,037.15
Eli Lilly
7D
-2.6%
1Y
27.9%

LLY: Government GLP 1 Pricing Deals Will Pressure Obesity Margins

Analysts have nudged their price targets on Eli Lilly slightly higher, citing continued confidence in the obesity and GLP 1 franchise, supportive government pricing agreements, and potential upside from acquisitions and pipeline catalysts, even as some firms fine tune their models and individual targets by low single digit amounts such as Guggenheim's recent US$2 trim. Analyst Commentary Recent research on Eli Lilly has been dominated by optimism around obesity treatments and government pricing agreements, but there is also a pocket of caution that is worth paying attention to if you are thinking about valuation, execution and long term growth risk.
PFE
US$26.44
Pfizer
7D
3.1%
1Y
-0.3%

PFE: Loss Of Exclusivity And Obesity Deal Costs Will Pressure Shares

Analysts have reduced their fair value estimate for Pfizer from $24.00 to $23.00 per share, citing lower revenue and margin assumptions, a slightly higher discount rate, and cautious views on patent expiries, while still noting ongoing interest in its pipeline and licensing deals. Analyst Commentary Recent Street research around Pfizer has been mixed, with some firms highlighting long term opportunities in areas like obesity and licensing, while others are stressing near term execution and patent expiry risks.
OCUL
US$9.14
Ocular Therapeutix
7D
-11.0%
1Y
18.7%
ZTS
US$124.82
Zoetis
7D
0.6%
1Y
-27.0%

ZTS: Fair Outlook Balances OA Pain Headwinds With New Antibody Approvals

Narrative update on Zoetis The analyst fair value estimate for Zoetis has been reset from US$153 to US$130 as analysts factor in slower expected revenue growth, a slightly higher discount rate, lower assumed future P/E multiples, and ongoing competitive and product launch headwinds highlighted in recent research. Analyst Commentary Recent research on Zoetis has tilted more cautious, with several bearish analysts resetting expectations around growth, execution, and what investors are willing to pay for the stock.
RPRX
US$41.68
Royalty Pharma
7D
3.2%
1Y
32.0%

RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside

Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.
JAZZ
US$164.49
Jazz Pharmaceuticals
7D
-2.5%
1Y
32.3%

JAZZ: Practice-Changing HER2 Data Will Rebalance Oncology Potential And Legacy Risks

Jazz Pharmaceuticals' updated analyst price target has edged down by US$1 to US$187 as analysts factor in slightly higher growth and margin assumptions, supported by recent HERIZON-GEA-01 data that they describe as practice changing for Ziihera and potentially supportive of new standard-of-care use across several HER2+ cancer settings. Analyst Commentary Across recent research, most firms are reacting to the HERIZON-GEA-01 data by lifting their Jazz Pharmaceuticals price targets and highlighting Ziihera and zanidatamab as key value drivers.
RGC
US$24.99
Regencell Bioscience Holdings
7D
-20.4%
1Y
24,890.0%